• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Social Work Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Med Fact Book App
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Is Topiramate a Silver Bullet for Those Dually Dependent on Alcohol and Nicotine?

Is Topiramate a Silver Bullet for Those Dually Dependent on Alcohol and Nicotine?

May 1, 2017
Kirsten Pickard, BA
From The Carlat Addiction Treatment Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Kirsten Pickard, BA Ms. Pickard has disclosed that she has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Review of: Anthenelli R et al, Alcohol Clin Exp Res 2017;41(1):197–206.

Study type: Randomized, double-blind, placebo-controlled trial

People with alcohol use disorder are often smokers, and it can be very hard for patients to reduce their drinking and smoking simultaneously. In this study, the researchers hypothesized that topiramate, which has shown promise as an off-label treatment for nicotine and alcohol use independently, might work as a “silver bullet” for both ­problems.

Methods
Researchers recruited 129 sober, alcohol-dependent male smokers for a 12-week, randomized, double-blind comparison of topiramate and placebo. The average participant was about 47 years old, was a veteran (62%), resided in a sober living facility where smoking was allowed (78%), and had at least one additional substance use disorder (80%) other than alcohol or tobacco. At the beginning of the study, all participants had smoked at least 10 cigarettes a day for the past 2 months but had abstained from alcohol for at least 1 month. Subjects were titrated to their maximum tolerable dose of topiramate (up to 100 mg bid) or placebo over 6 weeks, prior to their target quit date on day 43 (just after 6 weeks). They received their maximum dose through week 12, followed by a 1-week taper and 24-week follow-up period. All participants received smoking cessation and medication adherence counseling at each weekly visit. The primary end point was a minimum of 4 weeks of continuous abstinence, verified by carbon ­monoxide breath tests, and the secondary end point was relapse to drinking or drug use.

Results
No significant difference was found between the topiramate and placebo groups for either outcome. Topiramate and placebo groups saw rates of smoking cessation at just 7.9% and 10.6% respectively, while rates of relapse to alcohol and/or other drugs occurred at 31.8% and 27.3% respectively. Though topiramate relieved symptoms of nicotine withdrawal, it paradoxically increased self-reported urges to smoke in order to relieve negative affect. Topiramate didn’t affect time to alcohol relapse, and although it showed a significant initial reduction in smoking, this evened out to baseline over time.

CATR’s Take
This study suggests topiramate is not helpful for treating dual dependence on alcohol and nicotine. However, the authors described this study population as highly treatment-refractory with multiple negative predictors of success—such as living in an environment where social smoking was common—so these results may not generalize to other populations.

Treatment Implications
Don’t expect topiramate to work as a “twofer” for men who are smokers and newly abstinent drinkers, especially if they are living in a sober house with smoking housemates.
Addiction Treatment
KEYWORDS psychopharmacology
    Kirsten Pickard, BA

    Can a One-Week Naltrexone Detox Reduce Outpatient Opioid Relapse Rates?

    More from this author
    www.thecarlatreport.com
    Issue Date: May 1, 2017
    SUBSCRIBE NOW
    Table Of Contents
    Take The CME Post-Test for Recovery, CATR, May 2017
    Eight Strategies to Help Patients Maintain Recovery
    Recognizing and Reversing Relapse
    Treatment vs. Recovery
    Can a One-Week Naltrexone Detox Reduce Outpatient Opioid Relapse Rates?
    Is Topiramate a Silver Bullet for Those Dually Dependent on Alcohol and Nicotine?
    DOWNLOAD NOW
    Featured Book
    • OUDFB1e_Cover_Binding.png

      Treating Opioid Use Disorder—A Fact Book (2024)

      All the tools you need to assess and treat patients struggling with opioid use disorder. 
      READ MORE
    Featured Video
    • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
      General Psychiatry

      KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

      Read More
    Featured Podcast
    • shutterstock_2622607431.jpg
      General Psychiatry

      Should You Test MTHFR?

      MTHFR is a...
      Listen now
    Recommended
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png

    About

    • About Us
    • CME Center
    • FAQ
    • Contact Us

    Shop Online

    • Newsletters
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN Self-Assessment Courses

    Newsletters

    • The Carlat Psychiatry Report
    • The Carlat Child Psychiatry Report
    • The Carlat Addiction Treatment Report
    • The Carlat Hospital Psychiatry Report
    • The Carlat Geriatric Psychiatry Report
    • The Carlat Psychotherapy Report

    Contact

    carlat@thecarlatreport.com

    866-348-9279

    PO Box 626, Newburyport MA 01950

    Follow Us

    Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

    © 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.